Skip to main content

Table 1 Characteristics of acute myocardial infarction patients in the study

From: Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients

 

STEMI

NSTEMI

Diabetic

N = 2820

Non-diabetic

N = 3021

Diabetic

N = 2338

Non-diabetic

N = 1767

Age in years, median (IQR)

58.6 (51.4–66.2)

57.0 (50.5–64.9)

61.2 (54.0–70.0)

58.4 (50.9–66.9)

Male, n (%)

2289 (81.2)

2644 (87.5)

1695 (72.5)

1498 (84.8)

Race, n (%)

 Chinese

1457 (51.7)

1997 (66.1)

1208 (51.7)

1202 (68.0)

 Malay

714 (25.3)

574 (19.0)

550 (23.5)

305 (17.3)

 Indian

601 (21.3)

400 (13.2)

540 (23.1)

230 (13.0)

Past medical history, n (%)

 Hypertension

1854 (65.7)

1266 (41.9)

1876 (80.2)

963 (54.5)

 Diabetes

2142 (76.0)

NA

1994 (85.3)

NA

 Not on treatment

451 (21.1)

NA

257 (12.9)

NA

 Diet control

113 (5.3)

NA

102 (5.1)

NA

 Oral medication

1391 (64.9)

NA

1264 (63.4)

NA

 Insulin

64 (3.0)

NA

153 (7.7)

NA

 Oral medication & insulin

123 (5.7)

NA

218 (10.9)

NA

 Hyperlipidemia

1701 (60.4)

1070 (35.4)

1825 (78.1)

906 (51.3)

MI/PCI/CABG

499 (17.7)

319 (10.6)

963 (41.2)

337 (19.1)

Smoking, n (%)

 Current

1253 (44.9)

1602 (53.3)

750 (32.2)

806 (45.7)

 Former

422 (15.1)

365 (12.1)

468 (20.1)

315 (17.9)

 Never

1118 (40.0)

1039 (34.6)

1113 (47.7)

641 (36.4)

BMI in kg/m2, median (IQR)

25.2 (22.9–27.9)

24.4 (22.2–27.0)

25.6 (23.1–28.9)

24.8 (22.6–27.5)

Glucose in mmol/L, median (IQR)

13.8 (10.5–18.4)

7.8 (6.8–9.4)

12.3 (9.0–16.4)

6.7 (5.8–8.0)

HbA1c in %, median (IQR)

8.0 (6.9–9.9)

5.7 (5.5–6.0)

7.7 (6.8–9.3)

5.7 (5.5–6.0)

Total cholesterol in mmol/L, median (IQR)

4.9 (4.0–5.9)

5.2 (4.5–6.1)

4.7 (3.8–5.7)

5.2 (4.4–6.0)

LDL-cholesterol in mmol/L, median (IQR)

3.1 (2.4–4.0)

3.5 (2.8–4.3)

2.8 (2.2–3.7)

3.5 (2.7–4.2)

HDL-cholesterol in mmol/L, median (IQR)

1.0 (0.8–1.2)

1.1 (0.9–1.3)

1.0 (0.8–1.2)

1.0 (0.9–1.2)

Triglyceride in mmol/L, median (IQR)

1.5 (1.1–2.3)

1.3 (1.0–1.8)

1.7 (1.2–2.5)

1.5 (1.1–2.1)

Haemoglobin in g/dL, median (IQR)

14.6 (13.2–15.7)

14.8 (13.7–15.8)

13.7 (12.1–15.0)

14.5 (13.4–15.4)

Creatinine in µmol/L, median (IQR)

89 (74–112)

90 (77–105)

88 (72–116)

84 (73–97)

Killip class on admission, n (%)

 I

2261 (80.2)

2541 (84.1)

1790 (76.6)

1599 (90.5)

 II

196 (6.9)

126 (4.2)

322 (13.8)

94 (5.3)

 III

130 (4.6)

86 (2.9)

199 (8.5)

52 (2.9)

 IV

233 (8.3)

267 (8.8)

26 (1.1)

21 (1.2)

In-patient medication, n (%)

 Aspirin

2733 (96.9)

2956 (97.9)

2298 (98.3)

1722 (97.5)

 Beta-blocker

2457 (87.1)

2616 (86.6)

2121 (90.7)

1575 (89.1)

 ACEI/ARB

2171 (77.0)

2221 (73.5)

1930 (82.6)

1265 (71.6)

 Lipid lowering drug

2731 (96.8)

2955 (97.8)

2313 (98.9)

1755 (99.3)

 P2Y12 inhibitor

2773 (98.3)

2982 (98.7)

2330 (99.7)

1760 (99.6)

  1. ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, BMI body mass index, CABG coronary artery bypass grafting, IQR interquartile range, MI myocardial infarction, NA not applicable, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, SHR stress-hyperglycaemia ratio, STEMI ST-segment elevation myocardial infarction